Joshua D. Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joshua D. Smith has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
- Matthew E. Spector
Department of Otolaryngology Head & Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
37 shared publications - J. Chad Brenner
Department of Otolaryngology-Head and Neck Surgery, Michigan Medicine, Ann Arbor, Michigan
20 shared publications - Apurva D. Bhangale
Department of Otolaryngology-Head and Neck Surgery, Michigan Medicine, Ann Arbor, Michigan
19 shared publications - Christopher K. Bichakjian
Department of Dermatology, Michigan Medicine/University of Michigan, Ann Arbor, Michigan
19 shared publications - Collin Brummel
Department of Otolaryngology – Head & Neck Surgery, University of Michigan, Ann Arbor, Michigan
19 shared publications - Elizabeth Gensterblum-Miller
Department of Cellular and Molecular Biology, University of Michigan
19 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Elsevier in Oral Oncology
- Vol. 182
The impact of regional lymph node depletion on response to anti-PD-1 therapy in recurrent and metastatic head and neck squamous cell carcinoma
- 29 September 2026
- Published by Elsevier in Oral Oncology
- Vol. 182
Open AccessThe impact of regional lymph node depletion on response to anti-PD-1 therapy in recurrent and metastatic head and neck squamous cell carcinoma
- Open Access
- 28 September 2026
- Published by Wiley in World Journal of Otorhinolaryngology - Head and Neck Surgery
Audit of Patient Communications Following Transoral Robotic Surgery
Objective: To characterize patient‐initiated communications after transoral robotic surgery (TORS) for human papillomavirus positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) and assess associations with 30‐day emergency department (ED) presentation and hospital readmission. Methods: Retrospective review of adults undergoing TORS at a single tertiary center (July 2014–October 2021). Patient demographics, tumor characteristics, postoperative outcomes, and communications within 30 days were assessed. Logistic regression assessed associations with 30‐day ED presentation or readmission. Results: Among 249 patients (85.1% male; mean age 60.1 ± 9.9 years), 179 patients (71.8%) initiated communications, for a total of 448 individual communications (2.5 ± 1.8 per patient). Non‐medical concerns accounted for 58.0%, with medical concerns accounting for 42.0%. Fifty‐seven patients (22.9%) presented to the ED within 30 days; patients with ≥ 1 communication had higher ED presentation rates (27.9% vs. 10.0%, p = 0.002). On multivariate logistic regression, ≥ 1 communication (OR 2.98, 95% CI 1.12–7.87, p = 0.03) and longer duration from discharge to first postoperative appointment (OR 1.09, 95% CI 1.01–1.17, p = 0.03) remained significantly associated with 30‐day ED presentation. Notably, triaging providers recommended hospital presentation for only 16.0% of medical complaints. Conclusions: Patient‐initiated communications following TORS are common and mostly for logistical reasons. Communication frequency and time to first postoperative visit were predictive of 30‐day ED presentation, suggesting that adjusting time to first postoperative appointment, enhanced discharge education, and early postoperative check‐ins may be tangible methods to reduce unplanned healthcare utilization.
- 28 September 2026
- Published by Wiley in World Journal of Otorhinolaryngology - Head and Neck Surgery
Open AccessAudit of Patient Communications Following Transoral Robotic Surgery
Objective: To characterize patient‐initiated communications after transoral robotic surgery (TORS) for human papillomavirus positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) and assess associations with 30‐day emergency department (ED) presentation and hospital readmission. Methods: Retrospective review of adults undergoing TORS at a single tertiary center (July 2014–October 2021). Patient demographics, tumor characteristics, postoperative outcomes, and communications within 30 days were assessed. Logistic regression assessed associations with 30‐day ED presentation or readmission. Results: Among 249 patients (85.1% male; mean age 60.1 ± 9.9 years), 179 patients (71.8%) initiated communications, for a total of 448 individual communications (2.5 ± 1.8 per patient). Non‐medical concerns accounted for 58.0%, with medical concerns accounting for 42.0%. Fifty‐seven patients (22.9%) presented to the ED within 30 days; patients with ≥ 1 communication had higher ED presentation rates (27.9% vs. 10.0%, p = 0.002). On multivariate logistic regression, ≥ 1 communication (OR 2.98, 95% CI 1.12–7.87, p = 0.03) and longer duration from discharge to first postoperative appointment (OR 1.09, 95% CI 1.01–1.17, p = 0.03) remained significantly associated with 30‐day ED presentation. Notably, triaging providers recommended hospital presentation for only 16.0% of medical complaints. Conclusions: Patient‐initiated communications following TORS are common and mostly for logistical reasons. Communication frequency and time to first postoperative visit were predictive of 30‐day ED presentation, suggesting that adjusting time to first postoperative appointment, enhanced discharge education, and early postoperative check‐ins may be tangible methods to reduce unplanned healthcare utilization.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 - 2 of 3 from Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer
Co-mutation plot from targeted sequencing of 73 HPV- HNSCC patient tumors
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 - 2 of 3 from Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer
Co-mutation plot from targeted sequencing of 73 HPV- HNSCC patient tumors
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 - 1 of 2 from Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer
Co-mutation plot from targeted sequencing of 73 HPV- HNSCC patient lymph samples
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 - 1 of 2 from Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer
Co-mutation plot from targeted sequencing of 73 HPV- HNSCC patient lymph samples
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 - 1 of 2 from Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer
Orthogonal Validation of Lymph and Plasma MRD Detection.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 - 1 of 2 from Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer
Orthogonal Validation of Lymph and Plasma MRD Detection.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 - 2 of 2 from Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer
Orthogonal Validation of Lymph and Plasma MRD Detection.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 - 2 of 2 from Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer
Orthogonal Validation of Lymph and Plasma MRD Detection.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 - 2 of 3 from Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer
Lymph ctDNA outperforms pathology biomarkers.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 - 2 of 3 from Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer
Lymph ctDNA outperforms pathology biomarkers.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 - 3 of 3 from Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer
Supplementary Figure 2 shows frequency/patterns of observed tumor mutations in patient tumors
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 - 3 of 3 from Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer
Supplementary Figure 2 shows frequency/patterns of observed tumor mutations in patient tumors
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 - 1 of 3 from Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer
Lymph ctDNA outperforms pathology biomarkers.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 - 1 of 3 from Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer
Lymph ctDNA outperforms pathology biomarkers.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
STables 1-9 from Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer
STables 1-9: STable 1: H&N Panel regions. STable 2: Covariate analysis of cohort. STables 3 & 4: COX regression analysis. STables 5-7: Cohort Characteristics. STable 8: Lymph sequencing metrics. STable 9: Tumor mutations by patient.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSTables 1-9 from Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer
STables 1-9: STable 1: H&N Panel regions. STable 2: Covariate analysis of cohort. STables 3 & 4: COX regression analysis. STables 5-7: Cohort Characteristics. STable 8: Lymph sequencing metrics. STable 9: Tumor mutations by patient.